RS51255B - DOBIJANJE TNFR-Fc - Google Patents

DOBIJANJE TNFR-Fc

Info

Publication number
RS51255B
RS51255B RSP-2010/0190A RSP20100190A RS51255B RS 51255 B RS51255 B RS 51255B RS P20100190 A RSP20100190 A RS P20100190A RS 51255 B RS51255 B RS 51255B
Authority
RS
Serbia
Prior art keywords
medium
culture
glutamine
cells
conditions
Prior art date
Application number
RSP-2010/0190A
Other languages
English (en)
Serbian (sr)
Inventor
Denis Drapeau
Yen-Tung Luan
James R. Mercer
Wenge Wang
Daniel R. Lasko
Original Assignee
Wyeth Research Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35500648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51255(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Research Ireland Limited filed Critical Wyeth Research Ireland Limited
Publication of RS51255B publication Critical patent/RS51255B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RSP-2010/0190A 2004-08-27 2005-08-26 DOBIJANJE TNFR-Fc RS51255B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60537904P 2004-08-27 2004-08-27

Publications (1)

Publication Number Publication Date
RS51255B true RS51255B (sr) 2010-12-31

Family

ID=35500648

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP-2010/0190A RS51255B (sr) 2004-08-27 2005-08-26 DOBIJANJE TNFR-Fc
RSP-2009/0575A RS51072B (sr) 2004-08-27 2005-08-26 Dobijanje fuzionog proteina tnfr-ig

Family Applications After (1)

Application Number Title Priority Date Filing Date
RSP-2009/0575A RS51072B (sr) 2004-08-27 2005-08-26 Dobijanje fuzionog proteina tnfr-ig

Country Status (37)

Country Link
US (1) US7300773B2 (https=)
EP (2) EP1781802B1 (https=)
JP (3) JP2008511330A (https=)
KR (1) KR100988451B1 (https=)
CN (2) CN102876761A (https=)
AR (2) AR050537A1 (https=)
AT (2) ATE461285T1 (https=)
AU (1) AU2005280036B2 (https=)
BR (1) BRPI0514694B8 (https=)
CA (1) CA2578138C (https=)
CL (1) CL2017000577A1 (https=)
CR (2) CR8998A (https=)
CY (2) CY1109721T1 (https=)
DE (2) DE602005017285D1 (https=)
DK (2) DK1992697T3 (https=)
EC (1) ECSP077354A (https=)
EG (1) EG26922A (https=)
ES (2) ES2335518T3 (https=)
GT (2) GT200500233A (https=)
HN (1) HN2005000485A (https=)
HR (2) HRP20100011T1 (https=)
IL (1) IL181588A (https=)
MX (1) MX2007002381A (https=)
MY (1) MY137803A (https=)
NO (1) NO344785B1 (https=)
NZ (1) NZ579208A (https=)
PE (2) PE20060815A1 (https=)
PL (2) PL1781802T3 (https=)
PT (2) PT1781802E (https=)
RS (2) RS51255B (https=)
RU (1) RU2458988C2 (https=)
SI (2) SI1992697T1 (https=)
SV (1) SV2006002211A (https=)
TW (1) TWI364458B (https=)
UA (1) UA89383C2 (https=)
WO (1) WO2006026447A2 (https=)
ZA (1) ZA200701672B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
DK2041270T3 (da) * 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
EP2064315B1 (en) * 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
ES2538986T3 (es) * 2006-11-08 2015-06-25 Wyeth Llc Medios diseñados racionalmente para un cultivo celular
CA2679941C (en) * 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
TWI601823B (zh) 2007-04-26 2017-10-11 中外製藥股份有限公司 Cell culture methods using media containing high concentrations of amino acids
EP2310523B1 (en) * 2008-04-17 2015-06-10 Wyeth LLC Methods for enhanced production of bone morphogenetic proteins
US20110111495A1 (en) * 2008-04-18 2011-05-12 Shanghai Cp Guojian Pharmaceutical Co. Ltd Concentrated medium and its usage
WO2010016943A2 (en) * 2008-08-08 2010-02-11 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
SG185037A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
AU2011246502B2 (en) 2010-04-26 2014-08-28 Novartis Ag Improved cell cultivation process
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
WO2012068134A1 (en) 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
PL2702164T3 (pl) 2011-04-29 2016-06-30 Biocon Res Limited Sposób obniżania heterogeniczności przeciwciał i sposób ich wytwarzania
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
HK1200718A1 (en) 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
US20140322758A1 (en) * 2011-10-21 2014-10-30 Pfizer Inc. Addition of iron to improve cell culture
EP2817326A1 (en) * 2012-02-22 2014-12-31 NVIP Pty Ltd Tumour necrosis factor receptor fusion proteins and methods of using the same
IN2015KN00005A (https=) 2012-07-09 2015-07-31 Coherus Biosciences Inc
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG11201507875RA (en) 2013-03-26 2015-10-29 Coherus Biosciences Inc Protein production method
KR101439195B1 (ko) 2013-04-18 2014-09-12 동아대학교 산학협력단 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정
US20160244725A1 (en) * 2013-10-11 2016-08-25 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
BR112016017630A2 (pt) 2014-01-30 2017-08-08 Coherus Biosciences Inc Meios de perfusão
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105777897A (zh) * 2015-03-20 2016-07-20 广东东阳光药业有限公司 一种cho细胞收获液的前处理方法
JP6744324B2 (ja) * 2015-04-01 2020-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞培養培地
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
CN110484487A (zh) * 2019-08-21 2019-11-22 安徽欣乐生物技术有限公司 一种适用于cho细胞培养用无蛋白培养基及其培养方法
WO2022140389A1 (en) 2020-12-22 2022-06-30 Amgen Inc. Cell culture method
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
CN114480492B (zh) * 2022-01-28 2023-04-21 景泽生物医药(合肥)股份有限公司 一种重组人抗体融合蛋白的制备方法
CN119510778A (zh) * 2024-12-31 2025-02-25 北京同立海源生物科技有限公司 一种高稳定性的pdgf-bb活性检测方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU632065B2 (en) * 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
DK0494955T3 (da) * 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO2000023082A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
US7320790B2 (en) 2001-04-30 2008-01-22 Eli Lilly And Company Humanized antibodies
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2476887A1 (en) 2002-02-21 2003-09-04 Wyeth Gasp1:a follistatin domain containing protein
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SI2371392T1 (sl) 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法

Also Published As

Publication number Publication date
JP5921910B2 (ja) 2016-05-24
GT200500233A (es) 2006-03-09
EG26922A (en) 2014-12-25
JP2016056214A (ja) 2016-04-21
CA2578138C (en) 2010-10-05
ATE446376T1 (de) 2009-11-15
PE20060815A1 (es) 2006-09-14
ECSP077354A (es) 2007-05-30
GT200500234A (es) 2006-10-10
CR20120560A (es) 2012-12-04
JP2012095672A (ja) 2012-05-24
HK1121497A1 (en) 2009-04-24
KR20070069140A (ko) 2007-07-02
CY1110092T1 (el) 2015-01-14
HK1099941A1 (en) 2007-08-31
BRPI0514694B1 (pt) 2019-04-24
US7300773B2 (en) 2007-11-27
JP2008511330A (ja) 2008-04-17
RS51072B (sr) 2010-10-31
MX2007002381A (es) 2007-06-15
NZ579208A (en) 2012-01-12
AR050537A1 (es) 2006-11-01
IL181588A (en) 2010-12-30
WO2006026447A3 (en) 2006-04-20
ES2335518T3 (es) 2010-03-29
UA89383C2 (ru) 2010-01-25
ATE461285T1 (de) 2010-04-15
WO2006026447A9 (en) 2006-06-01
PT1781802E (pt) 2010-01-04
DE602005020076D1 (de) 2010-04-29
CY1109721T1 (el) 2014-08-13
PL1992697T3 (pl) 2010-08-31
NO20071570L (no) 2007-05-23
CN102876761A (zh) 2013-01-16
KR100988451B1 (ko) 2010-10-18
HRP20100011T1 (hr) 2010-02-28
CL2017000577A1 (es) 2017-12-01
AU2005280036B2 (en) 2011-11-03
PT1992697E (pt) 2010-04-21
RU2458988C2 (ru) 2012-08-20
SI1992697T1 (sl) 2010-07-30
ES2341390T3 (es) 2010-06-18
NO344785B1 (no) 2020-04-27
DE602005017285D1 (https=) 2009-12-03
AR088824A2 (es) 2014-07-10
SV2006002211A (es) 2006-10-04
CA2578138A1 (en) 2006-03-09
RU2007108717A (ru) 2008-10-10
CR8998A (es) 2007-11-23
TW200619388A (en) 2006-06-16
WO2006026447A2 (en) 2006-03-09
EP1992697B1 (en) 2010-03-17
PL1781802T3 (pl) 2010-03-31
EP1992697A1 (en) 2008-11-19
BRPI0514694B8 (pt) 2021-05-25
EP1781802B1 (en) 2009-10-21
DK1992697T3 (da) 2010-05-17
AU2005280036A1 (en) 2006-03-09
IL181588A0 (en) 2007-07-04
MY137803A (en) 2009-03-31
DK1781802T3 (da) 2010-01-25
EP1781802A2 (en) 2007-05-09
CN101061231A (zh) 2007-10-24
HN2005000485A (es) 2009-06-09
PE20100448A1 (es) 2010-06-22
SI1781802T1 (sl) 2010-01-29
CN101061231B (zh) 2012-09-26
US20060121569A1 (en) 2006-06-08
ZA200701672B (en) 2012-04-24
TWI364458B (en) 2012-05-21
BRPI0514694A (pt) 2008-06-17
HRP20100271T1 (hr) 2010-06-30

Similar Documents

Publication Publication Date Title
RS51255B (sr) DOBIJANJE TNFR-Fc
EP1789571B1 (en) Production of TNFR-Ig in a large-scale production cell culture
CN101048512B (zh) 抗淀粉样β肽抗体的生产
AU2012200353B2 (en) PRODUCTION OF a-ABeta
HK1180013B (en) Production of polypeptides
HK1181073A (en) Production of tnfr-ig fusion protein
HK1121497B (en) Production of tnfr-fc
HK1180013A (en) Production of polypeptides
HK1099941B (en) Production of a tnfr-ig fusion protein
HK1100008B (en) Production of anti-amyloid beta antibodies